Evaluation of the usefulness of new functional tests using insulin and glucago
Not Applicable
Recruiting
- Conditions
- endocrine and metabolic disorder
- Registration Number
- JPRN-UMIN000051413
- Lead Sponsor
- Kanazawa university hospital Department of Endocrinology and metabolism
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Not provided
Exclusion Criteria
1) Within 2 months of last use of somatostatin receptor analogs. 2) In case of severe infection, before or after surgery, or serious trauma. 3) Other cases in which the principal investigator or subinvestigator determines that the subject is inappropriate for this study. 4) When arginine tolerance test and rapid peripheral calcium tolerance test are not necessary under normal medical practice.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association of arginine loading test and rapid calcium loading test results with changes in HbA1c levels Glucose, insulin, and glucagon responses after calcium injection (0,3,6,10 min) and arginine injection (0,30,60,90,120 min).
- Secondary Outcome Measures
Name Time Method 1. Changes in blood pressure and pulse rate 2. Changes in blood glucose and insulin sensitivity (FPG, GA, IRI, HOMA-R, QUICKI, CPI) 3. Changes in lipids (total cholesterol, HDL cholesterol, triglycerides) 4. Changes in renal function and electrolytes (BUN, Cre, Na, K, Cl, urinary Cr, urinary albumin) 5. Bone effects (ALP, Ca, iP) and changes 6. Evaluation of safety and adverse events (Ht, Na, BUN, glycemic status, adverse events associated with drug administration)